Dyne Therapeutics, Inc. (DYN)
NASDAQ: DYN · Real-Time Price · USD
19.51
+0.30 (1.56%)
Apr 22, 2026, 10:38 AM EDT - Market open
Dyne Therapeutics Employees
Dyne Therapeutics had 258 employees as of December 31, 2025. The number of employees increased by 67 or 35.08% compared to the previous year.
Employees
258
Change
67
Growth
35.08%
Revenue / Employee
n/a
Profits / Employee
-$1,729,512
Market Cap
3.22B
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Dec 31, 2025 | 258 | 67 | 35.08% |
| Sep 30, 2025 | 240 | 67 | 38.73% |
| Jun 30, 2025 | 206 | 54 | 35.53% |
| Mar 31, 2025 | 192 | 49 | 34.27% |
| Dec 31, 2024 | 191 | 50 | 35.46% |
| Sep 30, 2024 | 173 | 37 | 27.21% |
| Jun 30, 2024 | 152 | 18 | 13.43% |
| Mar 31, 2024 | 143 | 21 | 17.21% |
| Dec 31, 2023 | 141 | 22 | 18.49% |
| Sep 30, 2023 | 136 | 21 | 18.26% |
| Jun 30, 2023 | 134 | 26 | 24.07% |
| Mar 31, 2023 | 122 | 26 | 27.08% |
| Dec 31, 2022 | 119 | 26 | 27.96% |
| Sep 30, 2022 | 115 | 27 | 30.68% |
| Jun 30, 2022 | 108 | 37 | 52.11% |
| Mar 31, 2022 | 96 | 40 | 71.43% |
| Dec 31, 2021 | 93 | 46 | 97.87% |
| Sep 30, 2021 | 88 | 52 | 144.44% |
| Jun 30, 2021 | 71 | 34 | 91.89% |
| Mar 31, 2021 | 56 | 19 | 51.35% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Sep 30, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| Telix Pharmaceuticals | 1,184 |
| Arcus Biosciences | 601 |
| Beam Therapeutics | 511 |
| Denali Therapeutics | 503 |
| Arcutis Biotherapeutics | 354 |
| Alumis | 224 |
| Structure Therapeutics | 220 |
| Catalyst Pharmaceuticals | 182 |
DYN News
- 21 days ago - Dyne Therapeutics Announces Participation at 2026 Academy of Managed Care Pharmacy (AMCP) Conference to Begin Shaping Access in US for Potential Neuromuscular Medicines - GlobeNewsWire
- 6 weeks ago - Dyne Therapeutics Announces Initiation of Phase 3 HARMONIA Trial of Z-Basivarsen in Myotonic Dystrophy Type 1 (DM1) - GlobeNewsWire
- 6 weeks ago - Dyne Therapeutics Announces New Positive Cardiopulmonary Results from DELIVER Trial of Z-Rostudirsen in Duchenne Muscular Dystrophy (DMD) - GlobeNewsWire
- 7 weeks ago - Dyne Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Recent Business Highlights - GlobeNewsWire
- 2 months ago - Dyne Therapeutics to Participate in Upcoming Investor Conferences - GlobeNewsWire
- 2 months ago - Dyne Therapeutics Announces Upcoming Presentations Across Neuromuscular Pipeline at 2026 MDA Clinical & Scientific Conference - GlobeNewsWire
- 2 months ago - Sparrow Appoints Biopharmaceutical Industry Veteran, Carlo Incerti, M.D. to its Board of Directors - GlobeNewsWire
- 3 months ago - Dyne Therapeutics Receives Orphan Drug Designation in Japan for Zeleciment Basivarsen (DYNE-101) for Myotonic Dystrophy Type 1 - GlobeNewsWire